Recent pre-clinical [298,299] and clinical studies [300] explored the applicability of olaparib synthetic lethality to cancers with disrupted ATM protein expression, specifically gastric cancer and mantle cell lymphoma (MCL). This evidence concerns the gene ATM and gastric cancer.